3,20-Dioxopregn-4-en-17-yl hexanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3,20-Dioxopregn-4-en-17-yl hexanoate
• 英文别名: (17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl) hexanoate
• 化学式: C₂₇H₄₀O₄
• 分子量: 428.6
• InChiKey: DOMWKUIIPQCAJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Treating auto-immune and auto-inflammatory diseases
  申请人：Shenzhen Evergreen Therapeutics Co., Ltd.

  公开号：US10987361B2

  公开（公告）日：2021-04-27

  The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.

  本发明涉及降低支气管肺泡灌洗液（BALF）和血液/血清中细胞因子白细胞介素-17（IL-17或IL-17A）水平和/或抑制p38丝裂原活化蛋白激酶（MAPK）活性的制剂、方法和试剂盒，涉及使用17α-羟基己酸孕酮（17-OHPC）或其衍生物。制剂可以是含有有效量 17-OHPC 的吸入剂形式，制剂可用于治疗 IL-17 细胞因子和/或 p38 MAPK 介导的自身免疫和自身炎症性疾病。此类疾病可包括对糖皮质激素（GC）不敏感的相关疾病或病症。在另一个实施方案中，制剂可包括布地奈德（BUD）与17-OPHC的联合使用。
• Treating Auto-Immune and Auto-Inflammatory Diseases
  申请人：Du Tao Tom

  公开号：US20160045517A1

  公开（公告）日：2016-02-18

  The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.